Zamtocabtagene autoleucel clinical trials
How each study uses zamtocabtagene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zamtocabtagene autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Miltenyi Biomedicine GmbH (7)
Often tested with
Tested in the same studies.
Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 (1) · Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test zamtocabtagene autoleucel.
- Dec 2026DALY II USA/ MB-CART2019.1 for DLBCLPhase 2 · Miltenyi Biomedicine GmbH
- Jan 2027DALY II Japan/MB-CART2019.1 for DLBCLPhase 2 · Miltenyi Biomedicine GmbH
Studies
Open first, then newest update. How each study uses zamtocabtagene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene TherapiesRecruitingNot applicableMiltenyi Biomedicine GmbHNCT06508775Written as MB-CART2019.1
- DALY II USA/ MB-CART2019.1 for DLBCLRecruitingPhase 2Miltenyi Biomedicine GmbHNCT04792489Written as zamtocabtagene autoleucel (MB-CART2019.1)
- US Zamto-cel Autoimmune DiseasesRecruitingPhase 1Miltenyi Biomedicine GmbHNCT06708845Written as zamtocabtagene autoleucel
- MB-CART2019.1 in Refractory Multiple SclerosisRecruitingPhase 1/2Miltenyi Biomedicine GmbHNCT07178431Written as MB-CART2019.1
- Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCLNot yet recruitingPhase 2Miltenyi Biomedicine GmbHNCT07569965Written as zamtocabtagene autoleucel (MB-CART2019.1)
- Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell NeoplasmsRecruitingPhase 2Miltenyi Biomedicine GmbHNCT06508931Written as zamtocabtagene autoleucel (MB-CART2019.1)
- DALY II Japan/MB-CART2019.1 for DLBCLRecruitingPhase 2Miltenyi Biomedicine GmbHNCT07288879Written as MB-CART2019.1
Codes
What other systems call zamtocabtagene autoleucel · ClinicalTrials.gg INT017405
- UNII (FDA) NT3BAN5MDVZAMTOCABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C180596Zamtocabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NT3BAN5MDV | ZAMTOCABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C180596 | Zamtocabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.